Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-05-08
2010-10-19
Weddington, Kevin (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S317000, C514S330000, C514S826000, C514S851000, C514S870000
Reexamination Certificate
active
07816374
ABSTRACT:
A therapeutic method is provided to treat neutrophil-associated pulmonary diseases, such as chronic obstructive pulmonary disease, by locally administering to a mammal in need of such treatment, an effective amount of a topical anesthetic, such as lidocaine, or a pharmaceutically acceptable salt thereof.
REFERENCES:
patent: 5510339 (1996-04-01), Gleich et al.
patent: 5631267 (1997-05-01), Gleich et al.
patent: 6861449 (2005-03-01), Gleich et al.
patent: 2006/0100276 (2006-05-01), Gleich et al.
patent: WO-92/14466 (1992-09-01), None
patent: WO-99/63985 (1999-12-01), None
Azuma et al., “Comparison of Inhibitory Effects of Local Anesthetics on Immune Function of Neutrophils”, International Journal of Immunopharmacology, vol. 22, No. 10, pp. 789-796 (Oct. 2000).
Downes et al., “Comparison of Local Anesthetics as Bronchodilator Aerosols”, Anesthesiology, vol. 58, No. 3, pp. 216-220 (Mar. 1983).
“U.S. Appl. No. 10/326,224, Amendment and Response filed May 24, 2004 to Non-Final Office Action mailed Feb. 24, 2004”, 8 pgs.
“U.S. Appl. No. 10/326,224, Non-Final Office Action mailed Feb. 24, 2004”, 7 pgs.
“U.S. Appl. No. 10/326,224, Notice of Allowance mailed Sep. 14, 2004”, 7 pgs.
“U.S. Appl. No. 10/326,224, PTO Response to 312 Communication mailed Jan. 12, 2005”, 2 pgs.
“U.S. Appl. No. 10/326,224, Response filed Oct. 10, 2003 to Restriction Requirement mailed Sep. 10, 2003”, 5 pgs.
“U.S. Appl. No. 10/326,224, Restriction Requirement mailed Sep. 10, 2003”, 4 pgs.
“U.S. Appl. No. 10/683,808, Non-Final Office Action mailed Apr. 26, 2004”, 7 pgs.
“U.S. Appl. No. 10/683,808, Non-Final Office Action mailed Jun. 15, 2005”, 6 pgs.
“U.S. Appl. No. 10/683,808, Non-Final Office Action mailed Nov. 19, 2004”, 5 pgs.
“U.S. Appl. No. 10/683,808, Response filed Mar. 21, 2005 to Non-Final Office Action mailed Nov. 19, 2004”, 9 pgs.
“U.S. Appl. No. 10/683,808, Response filed Jul. 23, 2004 to Non-Final Office Action mailed Apr. 25, 2004”, 11 pgs.
“U.S. Appl. No. 11/300,846, Final Office Action mailed Feb. 8, 2008”, 7 pgs.
“U.S. Appl. No. 11/300,846, Response filed Nov. 21, 2007 to Office Action mailed Jul. 25, 2007”, 11 pgs.
“U.S. Appl. No. 11/300,846, Response to Final Office Action mailed Feb. 8, 2008”, 9 pgs.
“U.S. Appl. No. 11/300,846, Advisory Action mailed Apr. 22, 2008”, 6 pgs.
“U.S. Appl. No. 11/300,846, Non-Final Office Action mailed May 18, 2006”, 6 pgs.
“U.S. Appl. No. 11/300,846, Non-Final Office Action mailed Jul. 25, 2007”, 6 pgs.
“U.S. Appl. No. 11/300,846, Response filed Aug. 18, 2006 to Non-Final Office Action mailed May 18, 2006”, 6 pgs.
“European Application Serial No. 01950391.1, Communication mailed Aug. 8, 2006”, 4 pgs.
“European Application Serial No. 01950391.1, Communication mailed Dec. 13, 2004”, 3 pgs.
“European Application Serial No. 01950391.1, Response filed Jun. 23, 2005 to Communication mailed Dec. 13, 2004”, 5 pgs.
“International Application Serial No. PCT/US01/19977, International Search Report mailed Mar. 20, 2002”, 4 pgs.
“International Application Serial No. PCT/US01/19977, International Preliminary Examination Report completed Mar. 21, 2002”, 2 pgs.
Abrosimov, V. N, “Inhalation of Lidocaine in Pulmonology”,Klinicheskaya Meditsina(Moscow), vol. 66, No. 12, (1988), 57-59.
Abrosimov, V. N., “Lidocaine Inhalations in pulmonary diseases”, (Abstract Only),Biosciences Information Service, Accession No. PREV198988077919, (1988), 1 pg.
Burner, U, et al., “Kinetics of oxidation of aliphatic and aromatic thiols by myeloperoxidase compounds I and II”,FEBS Lett., 443(3), (Jan. 29, 1999), 290-296.
Dahlen, J. R, et al., “Inhibition of neutrophil elastase by recombinant human proteinase inhibitor 9”,Biochim Biophys Acta, 1451(2-3), (Sep. 21, 1999), 233-241.
Fujisawa, T., et al., “The neutrophil and chronic allergic inflammation: immunochemical localization of neutrophil elastase”,Am Rev Respir Dis; vol. 141, (1990), 689-697.
Hattori, M, et al., “The inhibitory effects of local anesthetics on superoxide generation of neutrophils correlate with their partition coefficients”,Anesth Analg., 84(2), (Feb. 1997), 405-412.
Krasnowska, M., et al., “The use of lidocaine inhalation in Chronic bronchitis”,Pneumonologia Polska, vol. 54, No. 4 (Poland), (1986), 1 pg.
Krasnowska, Maryla, et al., “Application of Lidocaine Inhalation in Chronic Bronchitis”,Pneumonologia Polska, 54(4), (1986), 144-147.
Marfat, A., et al., “The discovery of CP-96,021 and CP-96,486,balanced,combined,potent and orally active leukotriene D4(LTD4)/platelet activating factor (PAF) receptor antagonists”,Bioorganic&Medicinal Chemistry Letters, 5(13), (Jul. 6, 1995), 1377-1382.
Pizzichini, Emilio, et al., “Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements”,American Journal of Respiratory and Critical Care Medicine, vol. 154, No. 2, (1996), 308-317.
Gleich Gerald J.
Hunt, Jr. Loren W.
Mayo Foundation for Medical Education and Research
Schwegman Lundberg & Woessner, P.A.
Weddington Kevin
LandOfFree
Method of treating neutrophil-related diseases with topical... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating neutrophil-related diseases with topical..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating neutrophil-related diseases with topical... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4240617